Project Details
Description
A randomized, double-blindphase 3 study of vadastuximab talirine (SGN-CD33A)versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) (SGN33A-005)
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/17 → 9/1/17 |
Funding
- SEAGEN INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.